nach oben

Current HIV/AIDS Reports

Erschienen in:

05.09.2017 | The Science of Prevention (JD Stekler and J Baeten, Section Editors)

Public Health and Public Order Outcomes Associated with Supervised Drug Consumption Facilities: a Systematic Review

verfasst von: Mary Clare Kennedy, Mohammad Karamouzian, Thomas Kerr

Erschienen in: Current HIV/AIDS Reports | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Supervised drug consumption facilities (SCFs) have increasingly been implemented in response to public health and public order concerns associated with illicit drug use. We systematically reviewed the literature investigating the health and community impacts of SCFs.

Recent Findings

Consistent evidence demonstrates that SCFs mitigate overdose-related harms and unsafe drug use behaviours, as well as facilitate uptake of addiction treatment and other health services among people who use drugs (PWUD). Further, SCFs have been associated with improvements in public order without increasing drug-related crime. SCFs have also been shown to be cost-effective.

Summary

This systematic review suggests that SCFs are effectively meeting their primary public health and order objectives and therefore supports their role within a continuum of services for PWUD. Additional studies are needed to better understand the potential long-term health impacts of SCFs and how innovations in SCF programming may help to optimize the effectiveness of this intervention.

Nur mit Berechtigung zugänglich

UNAIDS. UNAIDS global report [Internet]. 2013 [cited 2017 May 30]. Available from: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf

Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health. 2001;91(7):1060–8.CrossRefPubMedPubMedCentral

Doherty MC, Garfein RS, Vlahov D, Junge B, Rathouz PJ, Galai N, et al. Discarded needles do not increase soon after the opening of a needle exchange program. Am J Epidemiol. 1997;145(8):730–7.CrossRefPubMed

Center for Disease Control and Prevention, National Vital Statistics System, Mortality File. Number and age-adjusted rates of drug-poisoning deaths involving opioid analgesics and heroin: United States, 2000–2014 [Internet]. Atlanta: Center for Disease Control and Prevention; 2015 [cited 2017 Apr 7]. Available from: http://www.cdc.gov/nchs/data/health_policy/AADR_drug_poisoning_involving_OA_Heroin_US_2000-2014.pdf

Wood E, Kerr T, Small W, Li K, Marsh DC, Montaner JSG, et al. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. Can Med Assoc J. 2004;171(7):731–4.CrossRef

• Potier C, Laprévote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48–68. This systematic review includes descriptive, qualitative and feasibility studies specific to supervised injection facilities not included in the present study. CrossRefPubMed

• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug consumption rooms: an overview of provision and evidence [Internet]. 2016 [cited 2017 May 12]. Available from: http://www.emcdda.europa.eu/topics/pods/drug-consumption-rooms. This report provides a recent overview of the global distribution of supervised consumption facilities and a summary of the evidence on effectiveness.

Hedrich D, Kerr T, Dubois-Arber F. Drug consumption facilities in Europe and beyond. In: Rhodes T, Hedrich D, editors. Harm reduction: evidence, impacts, and challenges. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2010. p. 306–31.

Woods S. Drug consumption rooms in Europe: organizational overview [Internet]. Peacey J, Geise M, editors. European Harm Reduction Network. Amsterdam: Regenboog Groep; 2014 [cited 2017 Jun 14]. Available from: http://www.eurohrn.eu/images/stories/pdf/publications/dcr_in_europe.pdf

10.

Kennedy MC, Kerr T. Overdose prevention in the United States: a call for supervised injection sites. Am J Public Health. 2017;107(1):42–3.CrossRefPubMed

11.

Wood E, Tyndall MW, Lai C, Montaner JS, Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev Policy. 2006;1:13.CrossRefPubMedPubMedCentral

12.

Rapid Response Service. Rapid response: what is the effectiveness of supervised injection services? [Internet]. Ontario HIV Treatment Network; 2014 [cited 2017 Jun 8]. Available from: http://www.ohtn.on.ca/Pages/Knowledge-Exchange/Rapid-Responses/Documents/RR83-Supervised-Injection-Effectiveness.pdf

13.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRefPubMedPubMedCentral

14.

National Heart, Blood and Lung Institute. Quality assessment tool for observational cohort and cross-sectional studies. [Internet]. 2014 [cited 2017 May 14]. Available from: http://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort

15.

National Heart, Blood and Lung Institute. Quality assessment tool for before-after (pre-post) studies. [Internet]. 2014 [cited 2017 May 14]. Available from: https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/before-after

16.

Joanna Briggs Institute. Joanna Briggs Institute Critical Appraisal Checklist for Economic Evaluations. [Internet]. 2016 [cited 2017 May 14]. Available from: http://joannabriggs.org/research/critical-appraisal-tools.html

17.

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRefPubMedPubMedCentral

18.

Poschadel S, Höger R, Schnitzler J, Schreckenberger J. Evaluation der Arbeit der Drogenkonsumräume in der Bundesrepublik Deutschland: Endbericht im Auftrag des Bundesministeriums für Gesundheit, Das Bundesministerium für Gesundheit und Soziale Sicherung (Schriftenreihe Bd 149). Baden-Baden: Nomos- Verlags-Gesellschaft; 2003.

19.

Zurhold H, Degkwitz P, Verthein U, Haasen C. Drug consumption rooms in Hamburg, Germany: evaluation of the effects on harm reduction and the reduction of public nuisance. J Drug Issues. 2003;33(3):663–88.CrossRef

20.

Hedrich D. European report on drug consumption rooms [Internet]. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2004 [cited 2017 May 20]. Available from: http://www.emcdda.europa.eu/html.cfm/index54125EN.html

21.

van Beek I, Kimber J, Dakin A, Gilmour S. The Sydney medically supervised injecting centre: reducing harm associated with heroin overdose. Crit Public Health. 2004;14(4):391–406.CrossRef

22.

Freeman K, Jones C, Weatherburn D, Rutter S, Spooner C, Donnelly N. The impact of the Sydney Medically Supervised Injecting Centre (MSIC) on crime. Drug Alcohol Rev. 2005;24(2):173–84.CrossRefPubMed

23.

Kerr T, Tyndall M, Li K, Montaner J, Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet. 2005;366(9482):316–8.CrossRefPubMed

24.

Thein H, Kimber J, Maher L, MacDonald M, Kaldor J. Public opinion towards supervised injecting centres and the Sydney Medically Supervised Injecting Centre. Int J Drug Policy. 2005;16(4):275–80.CrossRef

25.

Wood E, Tyndall MW, Stoltz J-A, Small W, Lloyd-Smith E, Zhang R. Factors associated with syringe sharing among users of a medically supervised safer injecting facility. Am J Infect Dis. 2005;1(1):50–4.CrossRef

26.

Kerr T, Stoltz J-A, Tyndall M, Li K, Zhang R, Montaner J, et al. Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. BMJ. 2006;332(7535):220–2.CrossRefPubMedPubMedCentral

27.

Wood E, Tyndall MW, Zhang R, Stoltz J-A, Lai C, Montaner JSG, et al. Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med. 2006;354(23):2512–4.CrossRefPubMed

28.

Kerr T, Tyndall M., Zhang R, Lai C, Montaner J., Wood E. Circumstances of first injection among illicit drug users accessing a medically supervised safer injection facility. Am J Public Health. 2007;97(7).

29.

NCHECR. Sydney Medically Supervised Injecting Centre evaluation report no. 4: evaluation of service operation and overdose-related events [Internet]. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales; 2007 [cited 2017 Jun 7]. Available from: https://kirby.unsw.edu.au/report/sydney-medically-supervised-injecting-centre-msic-evaluation-report-4

30.

Salmon A, Thein H, Kimber J, Kaldor J, Maher L. Five years on: what are the community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre? Int J Drug Policy. 2007;18(1):46–53.CrossRefPubMed

31.

Stoltz J-A, Wood E, Small W, Li K, Tyndall M, Montaner J, et al. Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health. 2007;29(1):35–9.CrossRef

32.

Wood E, Tyndall MW, Zhang R, Montaner JSG, Kerr T. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction. 2007;102(6):916–9.CrossRefPubMed

33.

Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver’s supervised injection facility. Can Med Assoc J. 2008;179(11):1143–51.CrossRef

34.

Kimber J, Kimber J, Mattick RP, Kimber J, Mattick RP, Kaldor J, et al. Process and predictors of drug treatment referral and referral uptake at the Sydney Medically Supervised Injecting Centre. Drug Alcohol Rev. 2008;27(6):602–12.CrossRefPubMed

35.

Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T. Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health. 2008;8(1):405.CrossRefPubMedPubMedCentral

36.

Milloy M-JS, Kerr T, Mathias R, Zhang R, Montaner JS, Tyndall M, et al. Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility. Am J Drug Alcohol Abuse. 2008;34(4):499–509.CrossRefPubMed

37.

Milloy M-J, Kerr T, Tyndall M, Montaner J, Wood E. Estimated drug overdose deaths averted by North America’s first medically-supervised safer injection facility. PLoS ONE. 2008;3(10).

38.

Richardson L, Wood E, Zhang R, Montaner J, Tyndall M, Kerr T. Employment among users of a medically supervised safer injection facility. Am J Drug Alcohol Abuse. 2008;34(5):519–25.CrossRefPubMed

39.

Wood RA, Wood E, Lai C, Tyndall MW, Montaner JSG, Kerr T. Nurse-delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver’s supervised injection facility. Int J Drug Policy. 2008;19(3):183–8.CrossRefPubMed

40.

Bravo MJ, Royuela L, De la Fuente L, Brugal MT, Barrio G, Domingo-Salvany A, et al. Use of supervised injection facilities and injection risk behaviours among young drug injectors. Addiction. 2009;104(4):614–9.CrossRefPubMed

41.

Marshall BDL, Wood E, Zhang R, Tyndall MW, Montaner JSG, Kerr T. Condom use among injection drug users accessing a supervised injecting facility. Sex Transm Infect. 2009;85(2):121–6.CrossRefPubMed

42.

Milloy M-J, Wood E, Tyndall M, Lai C, Montaner J, Kerr T. Recent incarceration and use of a supervised injection facility in Vancouver, Canada. Addict Res Theory. 2009;17(5):538–45.CrossRef

43.

Andresen M, Boyd N. A cost-benefit and cost-effectiveness analysis of Vancouver’s supervised injection facility. Int J Drug Policy. 2010;21(1):70–6.CrossRefPubMed

44.

Baars JE, Boon BJF, Garretsen HFL, van de Mheen D. The reach of a free hepatitis B vaccination programme: results of a Dutch study among drug users. Int J Drug Policy. 2010;21(3):247–50.CrossRefPubMed

45.

Fitzgerald J, Burgess M, Snowball L. Trends in property and illicit drug crime around the Medically Supervised Injecting Centre in Kings Cross: an update [Internet]. 2010 [cited 2017 May 27]. Available from: http://www.bocsar.nsw.gov.au/Documents/BB/bb51.pdf

46.

Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Sheps S, Montaner JS, et al. Determinants of hospitalization for a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health. 2010;10(1):327.CrossRefPubMedPubMedCentral

47.

Milloy M-JS, Kerr T, Zhang R, Tyndall M, Montaner J, Wood E. Inability to access addiction treatment and risk of HIV infection among injection drug users recruited from a supervised injection facility. J Public Health. 2010;32(3):342–9.CrossRef

48.

Pinkerton S. Is Vancouver Canada’s supervised injection facility cost-saving? Addiction. 2010;105(8):1429–36.CrossRefPubMed

49.

Salmon AM, Van Beek I, Amin J, Kaldor J, Maher L. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. Addiction. 2010;105(4):676–83.CrossRefPubMed

50.

Scherbaum N, Specka M, Schifano F, Bombeck J, Marrziniak B. Longitudinal observation of a sample of German drug consumption facility clients. Subst Use Misuse. 2010;45(1–2):176–89.CrossRefPubMed

51.

DeBeck K, Kerr T, Bird L, Zhang R, Marsh D, Tyndall M, et al. Injection drug use cessation and use of North America’s first medically supervised safer injecting facility. Drug Alcohol Depend. 2011;113(2–3):172–6.CrossRefPubMed

52.

Marshall BD, Milloy M-J, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429–37.CrossRefPubMed

53.

Pinkerton SD. How many HIV infections are prevented by Vancouver Canada’s supervised injection facility? Int J Drug Policy. 2011;22(3):179–83.CrossRefPubMed

54.

Lloyd-Smith E, Tyndall M, Zhang R, Grafstein E, Sheps S, Wood E, et al. Determinants of cutaneous injection-related infections among injection drug users at an emergency department. Open Infect Dis J. 2012;6

55.

Donnelly N, Mahoney N. Trends in property and illicit drug crime around the Medically Supervised Injecting Centre in Kings Cross: 2012 update [Internet]. 2013 [cited 2017 May 27]. Available from: http://www.bocsar.nsw.gov.au/Documents/BB/bb90.pdf

56.

Vecino C, Villalbi J, Guitart A, Espelt A, Bartroli M, Castellano Y, et al. Apertura de espacios de consumo higienico y actuaciones policiales en zonas con fuerte trafico de drogas. Evaluacion mediante el recuento de las jeringas abandonadas en el espacio publico [Safe injection rooms and police crackdowns in areas with heavy drug dealing. Evaluation by counting discarded syringes collected from the public space]. Adicciones. 2013;25(4):333–8.CrossRefPubMed

57.

Jozaghi E, Vancouver Area Network of Drug Users. A cost-benefit/cost-effectiveness analysis of an unsanctioned supervised smoking facility in the downtown eastside of Vancouver, Canada. Harm Reduct J. 2014;11(1):30.CrossRefPubMedPubMedCentral

58.

Kinnard EN, Howe CJ, Kerr T, Skjødt Hass V, Marshall BD. Self-reported changes in drug use behaviors and syringe disposal methods following the opening of a supervised injecting facility in Copenhagen, Denmark. Harm Reduct J. 2014;11:29.CrossRefPubMedPubMedCentral

59.

Skelton E, Bonevski B, Tzelepis F, Shakeshaft A, Guillaumier A, Wood W, et al. Addressing tobacco smoking in a medically supervised injecting center with an organizational change intervention: an acceptability study. Asia Pac J Clin Oncol. 2016;12(Suppl. 6):13.

60.

Toth EC, Tegner J, Lauridsen S, Kappel N. A cross-sectional national survey assessing self-reported drug intake behavior, contact with the primary sector and drug treatment among service users of Danish drug consumption rooms. Harm Reduct J. 2016;13:27.CrossRefPubMedPubMedCentral

61.

Lysyshn M, Dohoo C, Forsting S, Kerr T, McNeil R. Evaluation of a fentanyl drug checking program for clients of a supervised injection site, Vancouver, Canada. In: 25th Harm Reduction International Conference Montreal, May 14–17 Abstract 188 [Internet]. 2017. Available from: https://www.hri.global/abstracts/abstrct/188/print

62.

Stoltz J-AM, Shannon K, Kerr T, Zhang R, Montaner JS, Wood E. Associations between childhood maltreatment and sex work in a cohort of drug-using youth. Soc Sci Med. 2007;65(6):1214–21.CrossRefPubMedPubMedCentral

63.

Andresen MA, Jozaghi E. The point of diminishing returns: an examination of expanding Vancouver’s Insite. Urban Stud. 2012;49(16):3531–44.CrossRef

64.

Wood E, Tyndall MW, Qui Z, Zhang R, Montaner JSG, Kerr T. Service uptake and characteristics of injection drug users utilizing North America’s first medically supervised safer injecting facility. Am J Public Health. 2006;96(5):770–3.CrossRefPubMedPubMedCentral

65.

Wood E, Tyndall MW, Li K, Lloyd-Smith E, Small W, Montaner JSG, et al. Do supervised injecting facilities attract higher-risk injection drug users? Am J Prev Med. 2005;29(2):126–30.CrossRefPubMed

66.

Kimber J, MacDonald M, van Beek I, Kaldor J, Weatherburn D, Lapsley H, et al. The Sydney Medically Supervised Injecting Centre: client characteristics and predictors of frequent attendance during the first 12 months of operation. J Drug Issues. 2003;33(3):639–48.CrossRef

67.

Milloy M-J, Wood E. Emerging role of supervised injecting facilities in human immodeficiency virus prevention. Addiction. 2009;104(4):620–1.CrossRefPubMed

68.

Minder Nejedly M, Bürki CM. Monitoring HIV risk behaviours in a street agency with injection room in Switzerland. Berne: Medical Faculty of the University in Berne; 1999.

69.

Reyes FV. 15 Jahre Fixerraum Bern. Auswirkungen auf soziale und medizinische Aspekte bei Drogenabhängigen. Berne: Medical Faculty of the University of Berne; 2003.

70.

Ronco S, Spuler G, Coda P, Schöpfer R. Evaluation der Gassenzimmer I, II und III in Basel. Soz- Präventivmedizin. 1996;41(Supplement 1):S58–68.CrossRef

71.

Ronco C, Spuhler G, Kaiser R. Evaluation des “Aufenthalts- und Betreuungsraums für Drogenabhängige” in Luzern [Evaluation of a stay and care center for drug addicts in Lucerne]. Soz- Präventivmedizin. 1996;41(Supplement 1):S45–57.CrossRef

72.

Benninghoff F, Solai S, Huissoud T, Dubois-Arber F. Evaluation de Quai 9 “Espace d”acceuil et d’injection’ à Genéve: période 12/2001–12/2000, Raisons de santé 103. Lausanne: Institut universitaire de médecine sociale et préventive; 2003.

73.

Benninghoff F, Geense R, Dubois-Arber F. Resultats de l’étude “La clientèle des structures à bas seuil d”accessibilité en Suisse. Lausanne: Institut universitaire de médecine sociale et préventive; 2001.

74.

Benninghoff F, Dubois-Arber F. Résultats de l’étude de la clientèle du Cactus BIEL/BIENNE 2001. Lausanne: Institut universitaire de médecine sociale et préventive; 2002.

75.

Solai S, Benninghoff F, Meystre-Agustoni G, Jeannin A, Dubois-Arber F. Evaluation de l’espace d’accueil et d’injection “Quai 9” à Genève: deuxième phase 2003. Lausanne: Institut universitaire de médecine sociale et préventive; 2004.

76.

Jacob J, Rottman J, Stöver H. Entstehung und Praxis eines Gesundheitsraumangebotes für Drogenkonsumierende. Abschlußbericht der einjährigen Evaluation des “drop-in Fixpunkt”/Hannover. Oldenburg: Schriftenreihe Sucht- Drog, 2, BIS–Verlag, Universität Oldenburg; 1999.

77.

van der Poel A, Barendregt C, van de Mheen D. Drug consumption rooms in Rotterdam: an explorative description. Eur Addict Res. 2003;9:94–100.CrossRefPubMed

78.

Zurhold H, Kreuzfeld N, Degkwitz P, Verthein U. Drogenkonsumräume. Gesundheitsförderung und Minderung öffentlicher Belastungen in europäischen Grossstädten. Freiburg: Lambertus; 2001.

79.

Petrar S, Kerr T, Tyndall MW, Zhang R, Montaner JSG, Wood E. Injection drug users’ perceptions regarding use of a medically supervised safer injecting facility. Addict Behav. 2007;32(5):1088–93.CrossRefPubMed

80.

Kerr T, Small W, Moore D, Wood E. A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver’s safer injection facility. Int J Drug Policy. 2007;18(1):37–45.CrossRefPubMed

81.

Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235–48.CrossRefPubMed

82.

Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, et al. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013;17(9):2878–92.CrossRefPubMed

83.

Wood W. Distributing “take home” naloxone via Sydney medically supervised injecting centre: Where to from here? Drug Alcohol Rev. 2015;34:67.

84.

Collins A, Parashar S, Hogg R, Fernando S, Worthington C, McDougall P, et al. Integrated HIV care and service engagement among people living with HIV who use drugs in a setting with a community-wide treatment as prevention initiative: a qualitative study in Vancouver, Canada. J Int AIDS Soc. 2017;20(1).

85.

Ti L, Dong H, Kerr T, Turje R, Parashar S, Min J, et al. The effect of engagement in an HIV/AIDS integrated health programme on plasma HIV-1 RNA suppression among HIV-positive people who use illicit drugs: a marginal structural modelling analysis. HIV Med. 2017;18(8):580-586.

86.

McNeil R, Dilley LB, Guirguis-Younger M, Hwang SW, Small W. Impact of supervised drug consumption services on access to and engagement with care at a palliative and supportive care facility for people living with HIV/AIDS: a qualitative study. J Int AIDS Soc. 2014;17(1).

87.

Kappel N, Toth E, Tegner J, Lauridsen S. A qualitative study of how Danish drug consumption rooms influence health and well-being among people who use drugs. Harm Reduct J. 2016;13:20.CrossRefPubMedPubMedCentral

88.

Meyer JP, Althoff AL, Altice FL. Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis. 2013;57(9):1309–17.CrossRefPubMedPubMedCentral

89.

Fairbairn N, Milloy M-J, Zhang R, Lai C, Grafstein E, Kerr T, et al. Emergency department utilization among a cohort of HIV-positive injecting drug users in a Canadian setting. J Emerg Med. 2012;43(2):236–43.CrossRefPubMed

90.

Linssen. Gebruiksruimten. Een systematisch overzicht van de voorziening en de effecten ervan. 2003.

91.

Meijer G, de Jong A, Koeter M, Bielman B. Gebruik van de straat. Evaluatie gebruiksruimnte Binnenstad-Zuid Groningen. Groningen-Rotterdam: INTRAVAL; 2001.

92.

Spreyermann C, Willen C. Evaluationsbericht Öffnung der Kontakt- und Anlaufstellen für risikoärmere Konsumformen. Evaluation der Inhalationsräume der Kontakt- und Anlaufstellen Selnau und Seilergraben der Ambulanten Drogenhilfe Zürich [Internet]. 2003 [cited 2017 May 27]. Available from: http://www.indro-online.de/zuerich.pdf

93.

BC Centre for Excellence in HIV/AIDS. Evaluation of the supervised injection site: year one summary [Internet]. Vancouver: BC Centre for Excellence in HIV/AIDS; 2004 [cited 2017 May 27]. Available from: http://www.salledeconsommation.fr/_media/bc-centre-for-excellence-in-hiv-aids-evaluation-of-the-supervised-injection-site-year-one-summary-september-17-2004.pdf

94.

Christie T, Wood E, Schechter MT, O’Shaughnessy MV. A comparison of the new Federal Guidelines regulating supervised injection site research in Canada and the Tri-Council Policy Statement on Ethical Conduct for Research Involving Human Subjects. Int J Drug Policy. 2004;15(1):66–73.CrossRef

95.

Maher APL, Maher APL, Salmon A, Maher APL, Salmon A. Supervised injecting facilities: how much evidence is enough? Drug Alcohol Rev. 2007;26(4):351–3.CrossRefPubMed

96.

Worrall J. Evidence: philosophy of science meets medicine. J Eval Clin Pract. 2010;16(2):356–62.CrossRefPubMed

97.

Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305–10.CrossRefPubMedPubMedCentral

98.

Parkhurst JO, Abeysinghe S. What constitutes “good” evidence for public health and social policy-making? From hierarchies to appropriateness. Soc Epistemol. 2016;30(5–6):665–79.CrossRef

99.

Solai S, Dubois-Arber F, Benninghoff F, Benaroyo L. Ethical reflections emerging during the activity of a low threshold facility with supervised drug consumption room in Geneva, Switzerland. Int J Drug Policy. 2006;17(1):17–22.

100.

Wood E, Spittal PM, Kerr T, Small W, Tyndall MW, O’Shaughnessy MV, et al. Requiring help injecting as a risk factor for HIV infection in the Vancouver epidemic: implications for HIV prevention. Can J Public Health Rev Can Santee Publique. 2003;94(5):355–9.

101.

Fairbairn N, Small W, Van Borek N, Wood E, Kerr T. Social structural factors that shape assisted injecting practices among injection drug users in Vancouver. Canada: a qualitative study Harm Reduct J. 2010;7:20.PubMed

102.

O’Connell JM, Kerr T, Li K, Tyndall MW, Hogg RS, Montaner JS, et al. Requiring help injecting independently predicts incident HIV infection among injection drug users. J Acquir Immune Defic Syndr 1999. 2005;40(1):83–8.

103.

Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, et al. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend. 2007;87(1):39–45.CrossRefPubMed

104.

McNeil R, Small W, Lampkin H, Shannon K, Kerr T. “People knew they could come here to get help”: an ethnographic study of assisted injection practices at a peer-run “unsanctioned” supervised drug consumption room in a Canadian setting. AIDS Behav. 2013;18(3):473–85.CrossRef

105.

Fairbairn N, Small W, Shannon K, Wood E, Kerr T. Seeking refuge from violence in street-based drug scenes: women’s experiences in North America’s first supervised injection facility. Soc Sci Med. 2008;67(5):817–23.CrossRefPubMed

106.

McNeil R, Shannon K, Shaver L, Kerr T, Small W. Negotiating place and gendered violence in Canada’s largest open drug scene. Int J Drug Policy. 2014;25(3):608–15.CrossRefPubMed

107.

Kerr T, Mitra S, Kennedy MC, McNeil R. Supervised injection facilities in Canada: past, present, and future. Harm Reduct J. 2017;14:28.CrossRefPubMedPubMedCentral

108.

Schäeffer D, Stöever H, Weichert L. Drug consumption rooms in Europe: models, best practices and challenges. Amsterdam: European Harm Reduction Network; 2014.

109.

• McNeil R, Kerr T, Lampkin H, Small W. “We need somewhere to smoke crack”: an ethnographic study of an unsanctioned safer smoking room in Vancouver, Canada. Int J Drug Policy. 2015;26(7):645–52. This paper describes the impacts of a peer-run unsanctioned safer inhalation room in reducing potential for health-related harms among people who inhale drugs. CrossRefPubMedPubMedCentral

110.

Jozaghi E, Lampkin H, Andresen M. Peer-engagement and its role in reducing the risky behavior among crack and methamphetamine smokers of the Downtown Eastside community of Vancouver, Canada. Harm Reduct J. 2016;13(1):19.CrossRefPubMedPubMedCentral

111.

Ti L, Buxton J, Harrison S, Dobrer S, Montaner J, Wood E, et al. Willingness to access an in-hospital supervised injection facility among hospitalized people who use illicit drugs. J Hosp Med. 2015;10(5):301–6.CrossRefPubMedPubMedCentral

112.

BCC News. France's first drug room for addicts to inject opens in Paris [Internet]. 2016 October 11 [cited August 14 2017]. Available from: http://www.bbc.com/news/world-europe-37617360

113.

McNeil R, Kerr T, Pauly B, Wood E, Small W. Advancing patient-centered care for structurally vulnerable drug-using populations: a qualitative study of the perspectives of people who use drugs regarding the potential integration of harm reduction interventions into hospitals. Addiction. 2016;11(4):685–94.CrossRef

114.

Golden RE, Collins CB, Cunningham SD, Newman EN, Card JJ. Overview of structural interventions to decrease injection drug-use risk. In: Best evidence structural interventions for HIV prevention. New York, NY: Springer; 2013:41-121.

115.

Shannon K, Rusch M, Shoveller J, Alexson D, Gibson K, Tyndall MW. Mapping violence and policing as an environmental–structural barrier to health service and syringe availability among substance-using women in street-level sex work. Int J Drug Policy. 2008;19(2):140–7.CrossRefPubMed

Titel: Public Health and Public Order Outcomes Associated with Supervised Drug Consumption Facilities: a Systematic Review
verfasst von: Mary Clare Kennedy
Mohammad Karamouzian
Thomas Kerr
Publikationsdatum: 05.09.2017
Verlag: Springer US
Erschienen in: Current HIV/AIDS Reports / Ausgabe 5/2017
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-017-0363-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen